An interventional study of Placebo and FibreGum in Nutritional and Metabolic Diseases and Overweight, sponsored by University of Bern. Recruiting at 1 site in Switzerland. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Bern · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Overweight with a site in Switzerland — 7 open to participants now, 13 under way, 4 of them phase 3. Overweight · Switzerland.
Among the 38 studies in Overweight with a site in Switzerland, this one is the 6th largest by planned enrollment of the 29 interventional ones that give a count, is one of 7 that started in 2025, is one of 20 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 29th registered.
3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.
Browse Overweight studies →7 of the 38 studies in Overweight with a site in Switzerland are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Switzerland, Canada
Ages 18+
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18–60 · Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Ages 45–60 · Women only
Vrije Universiteit Brussel · Sites in Switzerland, Belgium
Ages 18–65
University of Zurich · Sites in Switzerland
Ages 18–40 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 538 Overweight studies recruiting now, 163 (30%) set no upper age limit and 348 (65%) stop at 75 or younger; 64 take children under 18; 206 take healthy volunteers.
This study: 25 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 6 · Phase 4 1
First in 2004; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 78 across 3,142 interventional studies indexed under Overweight.
Median enrollment 76 across the 29 interventional studies, 40 across the 9 observational. Of the 21 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 38 have an industry lead sponsor. The 10 most frequent:
University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.
University of Bern has 1 study filed under Overweight — fewer than ten, so there is no comparison to draw.
6 of the studies in Overweight with a site in Switzerland that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT06855784University Hospital, GenevaTime-Restricted Eating in Menopause and HOrmone-sensitive Breast Cancers (TREMHO) | 2027-03-01 |
| NCT06370845University Hospital, Basel, SwitzerlandABUNDANCE of A NATURAL ODOUR in HUMAN CEREBROSPINAL FLUID AFTER OLFACTORY EXPOSURE - the OLFO-Brain Study | 2027-08-31 |
| NCT07036692University of BernThe FaibaGo Study - Long-Term Weight Reduction Via Low-Threshold Intervention | 2027-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 38 studies in Overweight with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to assess the effect of a chewing gum containing galactooligosaccharides (GOS) on the body mass index (BMI), the metabolism and the oral and intestinal microbiomes in a population of overweight adults.
3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.
This study's planned enrollment of 120 is above the median of 78 across 3,142 interventional studies indexed under Overweight.
Browse Overweight studies →University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.
Compared within Overweight, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutritional and Metabolic Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Metabolic risk factor: at least one of the following criteria:
i. ≥ 5.7% ii. Elevated liver enzymes (ALAT, ASAT, Gamma-Glutamyltransferase (gGT) at least one above normal range of the assay used in the respective laboratory) iii. LDL-cholesterol > 3.0 mmol/l iv. Triglycerides > 1.7 mmol/l
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chewing gum containing maltitol powder
Dietary Supplement: Placebo
Chewing gums containing galactooligosaccharides (GOS)
Dietary Supplement: FibreGum
No chewing-gums
To chew every day during a period of 4 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
To chew every day during a period of 4 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
Change in the Body Mass Index (BMI) during intervention
Difference in the BMI measured at intervention start and intervention completion
Time frame: 4 months
Systolic blood pressures change during intervention
Difference in systolic blood pressure (mm Hg) between intervention completion and intervention start.
Time frame: 4 months
Diastolic blood pressures changes during intervention
Difference in diastolic blood pressure (mm Hg) between intervention completion and intervention start.
Time frame: 4 months
Self-reported weight changes during intervention
Difference in self-reported weight (kg) between intervention completion and intervention start.
Time frame: 4 months
Self-reported weight changes during follow-up
Difference in self-reported weight (kg) between end of follow-up period and intervention completion.
Time frame: 2 months from intervention completion (month 4) to end of follow-up period (month 6)
Waist circumference changes during intervention
Difference in waist circumference (cm) between between intervention completion and intervention start.
Time frame: 4 months
Waist circumference changes during follow-up
Difference in waist circumference (cm) between end of follow-up period and intervention completion.
Time frame: 2 months from intervention completion (month 4) to end of follow-up period (month 6)
Fasting blood glucose change during intervention
Difference in fasting blood glucose (mg/dL or mmol/L) between intervention completion and intervention start.
Time frame: 4 months
Fasting insulin change during intervention
Difference in fasting insulin (mIU/mL) between intervention completion and intervention start.
Time frame: 4 months
HOmeostatic Model Assessment of Insulin Resistance (HOMA-IR) index change during intervention
Difference in Homeostatic Model Assessment of Insulin Resistance Index (min:0 - max:10) between intervention completion and intervention start. Lower scores mean better outcome.
Time frame: 4 months
Hemoglobin A1c (HbA1c) change during intervention
Difference in HbA1c (mmol/mol) between intervention completion and intervention start.
Time frame: 4 months
Cholesterol change during intervention
Difference in Cholesterol (mg/dL) between intervention completion and intervention start.
Time frame: 4 months
Triglyceride change during intervention
Difference in Triglyceride (mg/dL) between intervention completion and intervention start.
Time frame: 4 months
High-density lipoproteins (HDL) change during intervention
Difference in HDL (mg/dL) between intervention completion and intervention start.
Time frame: 4 months
Low-density lipoproteins (LDL) change during intervention
Difference in LDL (mg/dL) between intervention completion and intervention start.
Time frame: 4 months
Neutrophils change during intervention
Difference in Neutrophils count (%) between intervention completion and intervention start.
Time frame: 4 months
Lymphocytes change during intervention
Difference in Lymphocytes count (%) between intervention completion and intervention start.
Time frame: 4 months
Monocyte change during intervention
Difference in Monocytes count (%) between intervention completion and intervention start.
Time frame: 4 months
Eosinophils change during intervention
Difference in Eosinophils count (%) between intervention completion and intervention start.
Time frame: 4 months
Basophils change during intervention
Difference in Basophils count (%) between intervention completion and intervention start.
Time frame: 4 months
Alanine Aminotransferase (ALAT) change during intervention
Difference in ALAT (U/L) between intervention completion and intervention start.
Time frame: 4 months
Aspartate Aminotransferase (ASAT) change during intervention
Difference in ASAT (U/L) between intervention completion and intervention start.
Time frame: 4 months
Calcifediol (25OH-Vitamin D3) change during intervention
Difference in Calcifediol (nmol/L) between intervention completion and intervention start.
Time frame: 4 months
Thyroid-Stimulating Hormone (TSH) change during intervention
Difference in TSH (mU/L) between intervention completion and intervention start.
Time frame: 4 months
Ferritin change during intervention
Difference in Ferritin (μg/L) between intervention completion and intervention start.
Time frame: 4 months
Proteinuria change during intervention
Difference in Proteinuria (g/24h) between intervention completion and intervention start.
Time frame: 4 months
Oral microbiome change during intervention
Change in oral microbiota as assessed by metagenomic sequencing from oral washes between intervention completion and intervention start.
Time frame: 4 months
Gut microbiome change during intervention
Change in intestinal microbiota-composition as assessed by metagenomic sequencing from stool samples between intervention completion and intervention start.
Time frame: 4 months
Breath metabolome change during intervention
Change in volatile compounds present in the breath detected by secondary electrospray ionization (SESI) source in combination with a high-resolution mass spectrometry (HR-MS) between intervention completion and intervention start.
Time frame: 4 months
Body composition change (body fat) during intervention
Change in body fat between intervention completion and intervention start.
Time frame: 4 months
Body composition change (lean mass) during intervention
Change in lean mass between intervention completion and intervention start.
Time frame: 4 months
Change in in-vitro response of faecal microbiota (alpha diversity) to a panel of prebiotic compounds during intervention
Change in community diversity (alpha diversity) assessed by metagenomic sequencing between intervention completion and intervention start.
Time frame: 4 months
Change in in-vitro response of faecal microbiota (beta diversity) to a panel of prebiotic compounds during intervention
Change in composition (beta diversity, differential abundance) assessed by metagenomic sequencing between intervention completion and intervention start.
Time frame: 4 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.
Of 1,314 non-industry interventional studies with no phase under Overweight, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 24 months is above that.
Counting every sponsor, half of 1,427 studies reached it within 17 months; a quarter within 7 and three quarters within 38.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Oct 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.